N Anthony Coles Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

N Anthony Coles is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1,714 shares of REGN, which is worth approximately $1.19 Million. The most recent transaction as insider was on Jan 02, 2026, when has been sold 155 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.71K

9.94% 3M change

9.94% 12M change

Total Value Held $1.19 Million

N ANTHONY COLES Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2026	BUY Grant, award, or other acquisition	-	155 Added 8.29%	1,714 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	166 Added 9.62%	1,559 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	135 Added 8.84%	1,393 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	165 Added 11.6%	1,258 Common Stock
Dec 28 2022	SELL Open market or private sale	$4,102,690 $712.52 p/Share	5,758 Reduced 84.05%	1,093 Common Stock
Dec 28 2022	BUY Exercise of conversion of derivative security	$2,466,727 $428.4 p/Share	5,758 Added 45.67%	6,851 Common Stock
Sep 06 2022	SELL Open market or private sale	$3,482,700 $580.45 p/Share	6,000 Reduced 84.59%	1,093 Common Stock

Sep 06 2022	BUY Exercise of conversion of derivative security	$2,236,560 $372.76 p/Share	6,000 Added 46.9%	6,793 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	191 Added 14.88%	1,093 Common Stock
Sep 15 2021	SELL Open market or private sale	$7,864,891 $658.26 p/Share	11,948 Reduced 92.98%	902 Common Stock
Sep 15 2021	BUY Exercise of conversion of derivative security	$4,339,633 $363.21 p/Share	11,948 Added 48.18%	12,850 Common Stock
Aug 18 2021	SELL Open market or private sale	$3,315,000 $650.0 p/Share	5,100 Reduced 84.97%	902 Common Stock
Aug 18 2021	BUY Exercise of conversion of derivative security	$1,761,897 $345.47 p/Share	5,100 Added 45.94%	6,002 Common Stock
Aug 17 2021	SELL Open market or private sale	$585,000 $650.0 p/Share	900 Reduced 49.94%	902 Common Stock
Aug 17 2021	BUY Exercise of conversion of derivative security	$310,923 $345.47 p/Share	900 Added 33.31%	1,802 Common Stock
Aug 13 2021	SELL Open market or private sale	$1,250,000 $625.0 p/Share	2,000 Reduced 68.92%	902 Common Stock
Aug 13 2021	BUY Exercise of conversion of derivative security	$690,940 $345.47 p/Share	2,000 Added 40.8%	2,902 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	248 Added 21.57%	902 Common Stock
Nov 13 2020	BUY Exercise of conversion of derivative security	$3,800 $345.47 p/Share	11 Added 1.65%	654 Common Stock

Also insider at

CRSP

CRISPR Therapeutics AG Healthcare

Director

CERE

Cerevel Therapeutics Holdings, Inc. Healthcare

YMTX

YUMANITY THERAPEUTICS, INC. Healthcare

Executive Chair

NAC

N Anthony Coles

Director

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Value

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN

Account